rss
J Neurol Neurosurg Psychiatry 1989;52:732-735 doi:10.1136/jnnp.52.6.732
  • Research Article

The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.

  1. W J Weiner,
  2. S A Factor,
  3. J R Sanchez-Ramos
  1. Department of Neurology, University of Miami School of Medicine, Florida 33136.

      Abstract

      (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a novel selective D2 agonist. The efficacy and safety of PHNO was studied in 10 Parkinsonian patients (Hoehn and Yahr Stage II or III) who continued to receive levodopa/carbidopa. At the lowest dose administered (0.25 mg tid), nine of the 10 patients improved with respect to rigidity, bradykinesia and tremor. At this dose there was one dropout because of severe orthostasis. Although there was a trend towards improvement in motor scores with the higher doses (0.5-1.0 mg tid), this was not statistically significant. At higher doses there were a total of four dropouts because of adverse effects such as nausea, vomiting and orthostatic hypotension. It appears that PHNO may prove to be efficacious in the treatment of Parkinson's disease.

      This Article

      1. Abstract
      2. PDF

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

      BMJ Careers - Latest neurology and neurosurgery jobs